Galactose-decorated liver tumor-specific nanoliposomes incorporating selective BRD4-targeted PROTAC for hepatocellular carcinoma therapy

Epidemiology and surveillance for hepatocellular carcinoma: New trends

(2020) Amit G. Singal et al.   JOURNAL OF HEPATOLOGY

MYC protein stability is negatively regulated by BRD4

(2020) Ballachanda N. Devaiah et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Nanoformulation of PROteolysis TArgeting Chimera targeting ‘undruggable’ c-Myc for the treatment of pancreatic cancer

(2020) Aishwarya Saraswat et al.   Nanomedicine

EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC

(2019) Yalei Yin et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Design and Synthesis of Galactose-Biotin Lipid Materials for Liposomes to Promote the Hepatoma Cell–Targeting Effect

(2019) Ruihua Ding et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Viramidine-Loaded Galactosylated Nanoparticles Induce Hepatic Cancer Cell Apoptosis and Inhibit Angiogenesis

(2019) Ahmed A. Abd-Rabou et al.   APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY

A global view of hepatocellular carcinoma: trends, risk, prevention and management

(2019) Ju Dong Yang et al.   Nature Reviews Gastroenterology & Hepatology

EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAFV600E Mutated Parent- and Vemurafenib-Resistant Melanoma

(2019) Yige Fu et al.   Pharmaceutics

BRD4 PROTAC as a novel therapeutic approach for the treatment of vemurafenib resistant melanoma: Preformulation studies, formulation development and in vitro evaluation

(2019) Drishti Rathod et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Development of Asialoglycoprotein Receptor-Targeted Nanoparticles for Selective Delivery of Gemcitabine to Hepatocellular Carcinoma

(2019) Anroop B. Nair et al.   MOLECULES

Upregulation of Mcl-1 inhibits JQ1-triggered anticancer activity in hepatocellular carcinoma cells

(2018) Hua-Peng Zhang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Liposomal Drug Delivery Systems and Anticancer Drugs

(2018) Temidayo Olusanya et al.   MOLECULES

Nanoparticle–liver interactions: Cellular uptake and hepatobiliary elimination

(2016) Yi-Nan Zhang et al.   JOURNAL OF CONTROLLED RELEASE

Tumor stromal disrupting agent enhances the anticancer efficacy of docetaxel loaded PEGylated liposomes in lung cancer

(2016) Ketan Patel et al.   Nanomedicine

PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer

(2016) Kanak Raina et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents

(2016) Olaf Klingbeil et al.   Cell Death & Disease

3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained

(2016) Michele Zanoni et al.   Scientific Reports

Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4

(2015) Michael Zengerle et al.   ACS Chemical Biology

Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4

(2015) Jing Lu et al.   CHEMISTRY & BIOLOGY

BRD4 promotes tumor growth and epithelial-mesenchymal transition in hepatocellular carcinoma

(2015) Pengfei Zhang et al.   INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY

Piperlongumine for Enhancing Oral Bioavailability and Cytotoxicity of Docetaxel in Triple-Negative Breast Cancer

(2015) Ketan Patel et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Principles of nanoparticle design for overcoming biological barriers to drug delivery

(2015) Elvin Blanco et al.   NATURE BIOTECHNOLOGY

Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression

(2015) Gong-Quan Li et al.   Oncotarget

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery

(2015) Lei-lei Fu et al.   Oncotarget

Advances and Challenges of Liposome Assisted Drug Delivery

(2015) Lisa Sercombe et al.   Frontiers in Pharmacology

3D cell culture systems modeling tumor growth determinants in cancer target discovery

(2014) Claudio R. Thoma et al.   ADVANCED DRUG DELIVERY REVIEWS

Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems

(2011) Arati Sharma et al.   Expert Opinion on Drug Metabolism & Toxicology

In vitro three-dimensional (3D) models in cancer research: An update

(2011) Lauren C. Kimlin et al.   MOLECULAR CARCINOGENESIS

Survivin regulation by HER2 through NF-κB and c-myc in irradiated breast cancer cells

(2010) Vassilis Papanikolaou et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Selective inhibition of BET bromodomains

(2010) Panagis Filippakopoulos et al.   NATURE

Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc–Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice

(2008) Jianxia Guo et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Transcriptional regulation of survivin by c-Myc in BCR/ABL-transformed cells: implications in anti-leukaemic strategy

(2008) Zhi Hong Fang et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE